

## **Concert Pharmaceuticals to Report Full Year 2016 Results on March 6, 2017, and Present at Upcoming Investor Conferences**

LEXINGTON, Mass.--(BUSINESS WIRE)-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2016, on Monday, March 6, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EST to discuss 2016 financial results and provide a business update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).

In addition, the Company today announced that it will present a corporate overview at the following upcoming investor conferences:

- | The 37<sup>th</sup> Annual Cowen and Company Healthcare Conference on March 6, 2017 at 2:40 p.m. EST in Boston, MA;
- | The 29<sup>th</sup> Annual ROTH Conference on March 14, 2017 at 11:30 a.m. PST in Dana Point, CA; and
- | The Barclays Global Healthcare Conference on March 16, 2017 at 9:30 a.m. EST in Miami, FL.

A live webcast of these presentations including the fourth quarter financial results may be accessed in the [Investors](#) section of the Company's website at [www.concertpharma.com](http://www.concertpharma.com). Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the fourth quarter financial results webcast will be available on Concert's website for three months. A replay of the investor conference webcasts will be available on Concert's website for two weeks following each presentation.

### **About Concert**

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company focused on applying its [DCE Platform®](#) (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company's approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a [broad pipeline](#) of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit [www.concertpharma.com](http://www.concertpharma.com).

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

View source version on [businesswire.com](http://businesswire.com): <http://www.businesswire.com/news/home/20170302005160/en/>

Concert Pharmaceuticals, Inc.  
Justine Koenigsberg, 781-674-5284  
[ir@concertpharma.com](mailto:ir@concertpharma.com)

Source: Concert Pharmaceuticals, Inc.

News Provided by Acquire Media